Compugen to Present at the Cantor Global Healthcare Conference

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN) announced that it will present at the Cantor Global Healthcare Conference on September 30, 2021, at 1:20 pm ET. The presentation will cover its advancements in cancer immunotherapy, particularly focusing on COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT. Both are in Phase 1 studies for treating solid and hematological tumors. A live webcast will be accessible via Compugen's website.

HOLON, Israel, Sept. 14, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 pm ET.

A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the event.

About Compugen  

Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies as a single agent and in dual, and triple combination. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Compugen's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com. 

Company contact:  

Yvonne Naughton, PhD  
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com  
Tel: +1 (628) 241-0071  

Investor Relations contact:

John Mullaly
LifeSci Advisors, LLC
Email: jmullaly@lifesciadvisors.com  
Tel: +1 (617) 429-3548

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-cantor-global-healthcare-conference-301376160.html

SOURCE Compugen Ltd.

FAQ

When is Compugen's presentation at the Cantor Global Healthcare Conference?

Compugen will present on September 30, 2021, at 1:20 pm ET.

What is the focus of Compugen's presentation?

The presentation will focus on its cancer immunotherapy advancements and clinical-stage products.

Where can I watch Compugen's presentation live?

The live webcast will be available on Compugen's Investor Relations section of their website.

What are the key products Compugen is discussing?

Compugen will discuss COM701 and COM902, which are in Phase 1 studies for treating various tumors.

What is the stock symbol for Compugen?

Compugen's stock symbol is CGEN.